| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Cdo | Director
2 companies
Jeremy R. Graff is See Remarks at ALLR and has filed Form 4s across 2 companies. Jeremy R. Graff's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $95K at current prices.
The biggest single holding is ALLR (~$91K) as See Remarks.
Jeremy R. Graff has 14 Form 4 filings on record from May 2023 to May 2026, across 2 companies: Director at IN8bio (INAB), 2023–2026; Allarity Therapeutics (ALLR), 2024–2026.
The 21 reported transactions were 9 option or other derivative awards, 4 stock awards, 3 option exercises and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $2K and no sales.
The only open-market purchase was 2,500 shares of INAB at an average $0.95 on September 13, 2023, about $2K. Twelve months later INAB was down 68%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 13, 2023 | INAB In8bio, Inc. | Director | Buy | 2,500 | $0.95 | $2,375.00 | New | +73.8% | -68.0% |